Novartis Return On Equity vs. Price To Sales
| NVS Stock | USD 103.54 0.74 0.71% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter 0.31821201 | Current Value 0.33 | Quarterly Volatility 0.08695123 |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.78 | 0.7327 |
|
| |||||
| Net Profit Margin | 0.17 | 0.3183 |
|
| |||||
| Operating Profit Margin | 0.18 | 0.2094 |
|
| |||||
| Pretax Profit Margin | 0.25 | 0.1955 |
|
| |||||
| Return On Assets | 0.11 | 0.1486 |
|
| |||||
| Return On Equity | 0.33 | 0.3182 |
|
|
For Novartis profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Novartis to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Novartis AG ADR utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Novartis's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Novartis AG ADR over time as well as its relative position and ranking within its peers.
Novartis |
Novartis' Revenue Breakdown by Earning Segment
Check out Correlation Analysis.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.846 | Dividend Share 3.919 | Earnings Share 5.73 | Revenue Per Share 24.543 | Quarterly Revenue Growth 0.089 |
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Novartis AG ADR Price To Sales vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Novartis's current stock value. Our valuation model uses many indicators to compare Novartis value to that of its competitors to determine the firm's financial worth. Novartis AG ADR is regarded fourth in return on equity category among its peers. It also is regarded fourth in price to sales category among its peers fabricating about 14.40 of Price To Sales per Return On Equity. At this time, Novartis' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Novartis by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Novartis Price To Sales vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Novartis |
| = | 0.29 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Novartis |
| = | 4.15 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Novartis Price To Sales Comparison
Novartis is currently under evaluation in price to sales category among its peers.
Novartis Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Novartis, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Novartis will eventually generate negative long term returns. The profitability progress is the general direction of Novartis' change in net profit over the period of time. It can combine multiple indicators of Novartis, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -3.8 B | -3.6 B | |
| Operating Income | 9.8 B | 9.9 B | |
| Income Before Tax | 9.1 B | 10.2 B | |
| Total Other Income Expense Net | -646 M | -613.7 M | |
| Net Income | 8.6 B | 8.8 B | |
| Income Tax Expense | 551 M | 523.5 M | |
| Net Income Applicable To Common Shares | 8 B | 9.8 B | |
| Net Income From Continuing Ops | 8.2 B | 10.8 B | |
| Interest Income | 627 M | 595.6 M | |
| Net Interest Income | -492 M | -516.6 M | |
| Change To Netincome | 3.3 B | 3.5 B | |
| Net Income Per Share | 7.11 | 7.46 | |
| Income Quality | 1.69 | 1.11 | |
| Net Income Per E B T | 1.63 | 1.71 |
Novartis Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Novartis. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Novartis position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Novartis' important profitability drivers and their relationship over time.
Use Novartis in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novartis position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novartis will appreciate offsetting losses from the drop in the long position's value.Novartis Pair Trading
Novartis AG ADR Pair Trading Analysis
The ability to find closely correlated positions to Novartis could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novartis when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novartis - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novartis AG ADR to buy it.
The correlation of Novartis is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novartis moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novartis AG ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Novartis can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Novartis position
In addition to having Novartis in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Printing and Publishing Thematic Idea Now
Printing and Publishing
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Printing and Publishing theme has 21 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Printing and Publishing Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.